| Trial ID # | NCT03353831; AGO-OVAR2.29 |
| Phase | III |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/PD-L1 |
| Drug Name | Atezolizumab |
| Alternate Drug Names | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A , MPDL3280A, RG7446 |
| Drugs in Trial | Atezolizumab, Bevacizumab, Liposomal doxorubicin, Paclitaxel |
| Eligible Participant | Platinum resistant ovarian cancer with 1-2 prior therapies or recurrent ovarian cancer with 3 prior therapies that is not considered for platinum-based chemotherapy |
| Patients Enrolled | 550; 73% w/ prior bevacizumab |
| Therapy Setting | Recurrence |
| Study Design | Double Blind, Randomized |
| Endpoints | ORR, DoR, PFS, OS, evaluated per RECIST |
| Efficacy | Pac/PLD+Bev+Ate (n=285) vs Pac/PLD+Bev+Placebo (n=289): ORR: 39.6 vs 43.5% Exploratory analysis; w/ prior bev, w/ paclitaxel chemotherapy: |
| Clinically Significant Adverse Events | Pac/PLD+Bev+Ate vs Pac/PLD+Bev+Placebo: |
| Conclusion | The addition of atezolizumab to single agent chemotherapy with bevacizumab does not significantly improve PFS or OS in platinum resistant recurrent ovarian cancer patients or recurrent ovarian cancer patients who are not candidates for platinum therapy |
| Reference | Marme F et al. Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study. J Clin Oncol 42, 2024 (suppl 17; abstr LBA5501) Marme F et al. Slide from presentation |